Ozempic vs. Wegovy vs. Zepbound: Which GLP-1 Is Right for You?

First: What Do These Medications Have in Common?

Ozempic, Wegovy, Zepbound, and Mounjaro are all GLP-1 receptor agonists. They work by mimicking gut hormones that signal fullness, slow stomach emptying, and reduce appetite. All require a prescription. Most are injectable — but that's changing fast. Oral GLP-1 options are now available or on the immediate horizon, and they're reshaping who can access this class of medication. All produce meaningful, clinically significant weight loss when used correctly.

Ozempic vs. Wegovy: Same Drug, Different Purpose

Here's the most common point of confusion: Ozempic and Wegovy contain the exact same active ingredient — semaglutide. The difference is FDA approval and dosing. Ozempic is FDA-approved for type 2 diabetes management. Wegovy is FDA-approved specifically for chronic weight management — and as of March 2026, Wegovy's injectable portfolio now spans three doses: 1.7 mg, 2.4 mg, and the newly approved Wegovy HD at 7.2 mg. The FDA approved Wegovy HD on March 19, 2026, making it the highest approved injectable semaglutide dose available. In the STEP UP trial, Wegovy HD produced a mean weight loss of 20.7% — putting it directly in tirzepatide territory. It is indicated for patients who have tolerated the 2.4 mg dose for at least four weeks and need additional weight reduction. When a physician prescribes Ozempic "off-label" for weight loss, they are using the diabetes version. But for patients needing maximum efficacy, Wegovy HD is now a compelling step-up option before considering surgical intervention.

Zepbound vs. Mounjaro: Same Story

Zepbound and Mounjaro both contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is the weight-loss branded version. Tirzepatide is a dual agonist — it activates both GLP-1 and GIP receptors, which appears to drive stronger appetite suppression and greater weight loss than semaglutide alone. Clinical trials show average weight loss of about 21% of body weight with tirzepatide at 72 weeks, compared to roughly 15% with semaglutide.

The New Oral Option: Wegovy Pill and Orforglipron

This is where the GLP-1 landscape gets genuinely exciting — and where Li Health Clinic stays current so you don't have to.

Oral Wegovy (oral semaglutide) received FDA approval for weight loss in late 2025, making it the first GLP-1 pill specifically approved for chronic weight management. It contains the same active ingredient as injectable Wegovy — semaglutide — but is taken once daily by mouth. For patients who are needle-averse or simply prefer a pill, this is a genuine game-changer. Early uptake has been remarkable, with reports suggesting it became one of the fastest drug launches in history. Weight loss results are slightly lower than the injectable form, but for many patients the tradeoff in convenience is absolutely worth it.

Orforglipron is Eli Lilly's oral GLP-1 — a once-daily pill that works differently from oral semaglutide at the molecular level, which means it doesn't require the strict fasting and timing requirements that oral semaglutide does. Clinical trial results have been strong, showing meaningful weight loss comparable to injectable options. FDA approval is anticipated by mid-2026. This may become the most accessible GLP-1 yet — no injections, no complicated dosing windows, and potentially broader affordability than brand-name injectables.

If needle aversion has been the reason you've held off on GLP-1 therapy, now is an excellent time to revisit that conversation with a physician.

Head-to-Head: Which Is More Effective?

In direct comparison studies, tirzepatide (Zepbound/Mounjaro) has consistently outperformed standard-dose semaglutide (Wegovy 2.4 mg/Ozempic) for weight loss. However, the new Wegovy HD at 7.2 mg changes that picture — its 20.7% mean weight loss in STEP UP is directly comparable to tirzepatide's results, giving patients who've plateaued on 2.4 mg a meaningful step-up within the same drug class. "More effective on average" still doesn't mean any one medication is right for everyone. Side effect profiles differ — Wegovy HD does carry a higher rate of GI side effects and a newly noted skin sensation called dysesthesia in some patients. Cost differs. Individual responses vary significantly. The best GLP-1 is the one you tolerate well, can access reliably, and will actually stay on.

Cost Comparison (Without Insurance, 2026)

Brand-name GLP-1 medications run $900–$1,300/month without insurance. As an obesity medicine physician, I help my patients identify manufacturer savings programs and patient assistance options — which can sometimes bring the cost down significantly.

Which Should You Choose?

This is a clinical decision that depends on your medical history, any existing conditions (especially diabetes or thyroid history), your weight loss goals, your budget, and how your body responds. It is not a decision to make based on social media trends. During your consultation, we review all of these factors together and choose the right starting point for you specifically.